Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (483)	2/28/2005 4:14:48 PM
From: Icebrg	of 946

Ian The reality is not as impressive as it might seem. The study was referred to during the CC and I already had the paper on my hard disk. The complete paper is available as a free download at JCO's webpage. It's supposed to be the gold standard as far as doublet treatment of first-line NSCLC is concerned. All in all a fairly strong indication that there indeed is a positive treatment effect. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next